Inmune Bio, Inc.
About Inmune Bio, Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $50.0K
- Net income
- -$45.9M
- Total assets
- $32.4M
- Market cap
- $33.5M
- Operating margin
- -94766.0%
- Net margin
- -91866.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $50.0K
- Operating expenses
- $47.4M
- Operating income
- -$47.4M
- Net income
- -$45.9M
- EPS (basic)
- $-1.86
- EPS (diluted)
- $-1.86
Balance sheet
- Total assets
- $32.4M
- Current assets
- $29.9M
- Total liabilities
- $8.8M
- Current liabilities
- $8.4M
- Shareholders’ equity
- $23.5M
Cash flow
- Operating cash flow
- -$22.6M
- Investing cash flow
- -$4.9M
- Financing cash flow
- $27.6M
- Net cash flow
- $159.0K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $33.5M
- EPS (diluted)
- $-1.86
- Shares outstanding
- 27.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 4, 2019
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $45.9M in FY2025.
- Revenue declined 72% from FY2021 to FY2025.
- Trading 85% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Inmune Bio, Inc..
Write a review
News about Inmune Bio, Inc.
News & sentiment via Polygon.io
